The OPTIMA Phase III Trial: Methodological Considerations, Comparison with RxPONDER, and Balanced Interpretation of Test-Directed Chemotherapy De-escalation
Global Advances in Oncology and Hematology · 2026-09 · 1 (1) · 31-35
DOI: 10.4103/gaoh.gaoh_2_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Advances in Oncology and Hematology, online erschienen am 05.09.2026. Verfasst von Nadia Abdel Wahed und 3 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wahed, N. A., Abdellatif, H., Ahmed, Y. K., & Jabbar, D. A. (2026). The OPTIMA Phase III Trial: Methodological Considerations, Comparison with RxPONDER, and Balanced Interpretation of Test-Directed Chemotherapy De-escalation. Global Advances in Oncology and Hematology, 1(1), 31-35. https://doi.org/10.4103/gaoh.gaoh_2_26
Vancouver
Wahed NA, Abdellatif H, Ahmed YK, Jabbar DA. The OPTIMA Phase III Trial: Methodological Considerations, Comparison with RxPONDER, and Balanced Interpretation of Test-Directed Chemotherapy De-escalation. Global Advances in Oncology and Hematology. 2026;1(1):31-35. doi:10.4103/gaoh.gaoh_2_26
BibTeX
@article{Wahed2026,
author = {Wahed, Nadia Abdel and Abdellatif, Hala and Ahmed, Yasin K. and Jabbar, Dima Abdul},
title = {The OPTIMA Phase III Trial: Methodological Considerations, Comparison with RxPONDER, and Balanced Interpretation of Test-Directed Chemotherapy De-escalation},
journal = {Global Advances in Oncology and Hematology},
year = {2026},
volume = {1},
number = {1},
pages = {31--35},
doi = {10.4103/gaoh.gaoh_2_26}
}
EUVIMED